Okamoto Mariko, Asamura Ai, Tanaka Ko, Soeda Takefumi, Watanabe Kyo, Mizuguchi Hiroyuki, Ikeda Teruo
Laboratory of Veterinary Immunology, Department of Veterinary Medicine, School of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa, 252-5201, Japan.
Laboratory of Biochemistry and Molecular Biology, Graduate School and School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Vet Res Commun. 2016 Dec;40(3-4):131-139. doi: 10.1007/s11259-016-9664-7. Epub 2016 Oct 16.
Adenovirus (Ad) vectors are widely used in cancer gene therapies. However, compared to human patients, relatively limited information is available on gene transduction efficiency or cell-specific cytotoxicity in canine tumor cells transduced with Ad vectors. Since epidermal growth factor receptor (EGFR) is highly expressed on canine breast tumor cells, we sought to develop an Ad vector based on the RGD fiber-mutant adenovirus vector (AdRGD) that expresses canine caspase 3 under the control of EGFR promoter. The aims of this study were to achieve high transduction efficiency with transgene expression restricted to canine breast tumor cells. Using EGFR promoter-driven AdRGD, we were able to restrict transgene expression to canine breast tumor cells with no evidence of expression in normal cells. Canine breast tumor cells transduced with EGFR promoter-driven AdRGD carrying canine caspase 3 gene showed cytotoxic activity. We constructed a second AdRGD vector that expressed oxygen-dependent degradation (ODD)-caspase 3 under the control of the EGFR promoter; the fusion protein contains a core part of the ODD domain of hypoxia inducible factor-1 alpha (HIF-1α) fused to caspase 3. Transduction of canine breast tumor cells with EGFR promoter-driven AdRGD expressing ODD-caspase 3 induced a higher rate of cell death under hypoxic conditions compared with under normoxia. The results indicate that the EGFR promoter-driven AdRGD vectors will be of value for tumor-specific transgene expression and safe cancer gene therapy in dogs.
腺病毒(Ad)载体广泛应用于癌症基因治疗。然而,与人类患者相比,关于腺病毒载体转导犬肿瘤细胞的基因转导效率或细胞特异性细胞毒性的信息相对有限。由于表皮生长因子受体(EGFR)在犬乳腺肿瘤细胞上高度表达,我们试图开发一种基于RGD纤维突变腺病毒载体(AdRGD)的腺病毒载体,该载体在EGFR启动子的控制下表达犬半胱天冬酶3。本研究的目的是在将转基因表达限制于犬乳腺肿瘤细胞的情况下实现高转导效率。使用EGFR启动子驱动的AdRGD,我们能够将转基因表达限制于犬乳腺肿瘤细胞,而在正常细胞中没有表达的证据。用携带犬半胱天冬酶3基因的EGFR启动子驱动的AdRGD转导的犬乳腺肿瘤细胞显示出细胞毒性活性。我们构建了第二种AdRGD载体,其在EGFR启动子的控制下表达氧依赖性降解(ODD)-半胱天冬酶3;该融合蛋白包含与半胱天冬酶3融合的缺氧诱导因子-1α(HIF-1α)的ODD结构域的核心部分。与常氧条件相比,用表达ODD-半胱天冬酶3的EGFR启动子驱动的AdRGD转导犬乳腺肿瘤细胞在缺氧条件下诱导更高的细胞死亡率。结果表明,EGFR启动子驱动的AdRGD载体对于犬的肿瘤特异性转基因表达和安全的癌症基因治疗具有价值。